April 6, 2011—U.S. House Republicans yesterday proposed converting the federal share of Medicaid spending into block grants to states, a move that could potentially imperil the 340B drug discount program. The plan, one of the main elements in the fiscal 2012 budget resolution issued by the House Budget Committee on April 5, is expected to face stiff opposition from President … [Read more...]
Drug Shortages Costing Hospitals $200 Million, Study Finds
Problem that exploded last year persists into 2011 and could be getting worse.April 1, 2011— Prescription drug shortages are forcing hospitals to spend an extra $200 million a year on more expensive substitutes and exposing patients to greater risk of medication errors, a leading group purchasing organization (GPO) reports. According to the study by the Premier health care alliance , providers are spending an extra 11 percent more on average for … [Read more...]
340B Providers Might Benefit From Closing of Medicaid Rebate “Loophole”
Provision in health care reform bill is aimed at preventing potential reformulation of drugs to avoid paying rebates.340B Providers Might Benefit From Closing of Medicaid Rebate "Loophole" March 30, 2010 - The health care reform package that President Obama signed today contains a little-noticed Medicaid drug rebate provision that could add up to significant savings for 340B providers and the Medicaid program. Backgrounder: Additional Medicaid Rebate for Brand-Name … [Read more...]
340B Providers Cannot Sue for Overcharges, U.S. Supreme Court Rules
Focus shifts to formal dispute resolution system that is still on the drawing board.March 29, 2011— The U.S. Supreme Court ruled today that 340B providers do not have a right to sue drug manufacturers for overcharges as the beneficiaries of pricing agreements between the companies and the federal government. The unanimous decision effectively ends a landmark case brought by two California countiesagainst nine major drug manufacturers alleging that they were … [Read more...]
Impasse Continues Over Federal 2011 Spending
Government shutdown looms.March 28, 2011—Congress has returned to work after a weeklong recess with the clock winding down on its latest stop-gap spending bill to keep federal agencies open. The current continuing resolution expires on April 8. If the Democratic-led Senate and the Republican-led House cannot come to an agreement the government will be forced to close, including the Office of Pharmacy … [Read more...]
Brand-Name Drug Prices Rising Sharply, Studies Find
340B inflation adjustment offers providers some relief.March 28, 2011—Four new studies—by an investment bank, a research firm, a health insurer and a congressional agency—conclude that brand-name drug prices have been outpacing inflation by a wide margin while generic drugs prices have been either falling or holding steady. U.S. House Democrats who commissioned one of the reports say the findings warrant a congressional … [Read more...]
Biogen Idec and Santarus to Provide 340B Refunds
Affected products include Biogen's blockbuster drug for multiple sclerosis.March 16, 2011—The manufacturer of Avonex, a leading treatment for relapsing-remitting multiple sclerosis (MS), has informed the Office of Pharmacy Affairs (OPA) that it will be repaying 340B covered entities for overcharges on the biotech drug during the fourth quarter of 2000 through the first quarter of 2008. The company, Biogen Idec, also told OPA that it was sending … [Read more...]